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Overall responsibilities of the data monitoring committee (DMC)
The DMC periodically reviewed the safety data of the trial for unexpected large differences or toxicity between the treatment groups.
The DMC functioned independently of all other individuals associated with the conduct of this trial, including investigators, and the sponsor. It was responsible for assuring the safety of the trial participants and that the trial was being conducted with high scientific and ethical standards. The DMC was responsible for assessing the safety data as defined by the study protocol during the trial, for monitoring the overall conduct of the trial on a periodic basis, and for making recommendations to the sponsor on actions including:
• Discontinuation of the trial (with provisions for orderly discontinuation in accordance with good clinical practice)
• Suggestion of modifications to the trial protocol; modifications may include, but were not The conversion factor for total testosterone, from ng/dL to nmol/L, is 0.0347. BSAP, bone-specific alkaline phosphatase; β-CTx, β-C-terminal telopeptide of type 1 collagen; NA, not applicable; PINP, procollagen I N-terminal propeptide; SE, standard error of the mean. Between treatment p-value is obtained from a logistic regression model with treatment, prevalent vertebral fracture, and region as explanatory variables. Interaction p-value is obtained from a logistic regression model with total testosterone and treatment by total testosterone interaction as additional explanatory variables. The conversion factor for total testosterone, from ng/dL to nmol/L, is 0.0347. CI, confidence intervals; NA, not applicable; RR, relative risk. Similar results were seen with BMD at total hip and femoral neck. For (b), between total testosterone subgroups comparison cannot be performed because no zoledronic acid-treated patient with serum total testosterone ≤230 ng/dL had BMD measurements. Between treatment p-value is obtained from an analysis of covariance model with treatment and baseline value as explanatory variables. Interaction p-value is obtained from the ANCOVA with total testosterone and treatment by Total testosterone interaction as additional explanatory variables. The conversion factor for total testosterone, from ng/dL to nmol/L, is 0.0347. NA, not applicable; SE, standard error of the mean. Only results from patients with Total testosterone measured by 12 noon are included in these tables. Similar log(e) β-CTx, PINP and BSAP ratios were seen at month 3, 6, 15 and 18.
For (b) between total testosterone subgroups comparison cannot be performed since no zoledronic acid-treated patient with serum total testosterone ≤230 ng/dL had BTM measurements.
Between treatment p-value is obtained from an analysis of covariance on log(e) (ratio) with treatment and log(e) (baseline value) as explanatory variables. Interaction p-value is obtained from the ANCOVA with total testosterone and treatment by total testosterone interaction as additional explanatory variables. The conversion factor for total testosterone, from ng/dL to nmol/L, is 0.0347. BSAP, bone-specific alkaline phosphatase; β-CTx, β-C-terminal telopeptide of type 1 collagen; CI, confidence interval; PINP, procollagen I N-terminal propeptide; SE, standard error of the mean. The 'completers' method included non-missing data only; subjects who had month 24 X-ray in the modified intent-to-treat population (patients who had baseline and ≥1 post-baseline assessment of the primary efficacy variable). The 'single imputation' method assigned 'no fracture' to all subjects who had undetermined fracture status at month 24 in the intent-to-treat population. The 'multiple imputation' method imputed undetermined fracture status at month 24 in the intent-to-treat population 200 times using a logistic regression model. Table A , results are based on data from patients included in the mITT population, which consisted of 553 patients in the zoledronic acid group and 574 patients in the placebo group; the relative risk was calculated based on a 2x2 table and the normal approximation was used to calculate its 95% CI. P-values were from logistic regression models, which included adjustments for prevalent vertebral fracture and region. For Table B , the hazard ratio and 95% CI were computed from a Cox proportional hazard regression model with treatment as a factor. The p-value was calculated from a log-rank test. For Table C , log hazard ratios from the HORIZON-PFT and -RFT were combined using the inverse variance meta-analysis method. The meta-analysis mean was used as the prior mean. The prior variance was the meta-analysis mean variance plus a between-trial variance that was used to discount these data. The 95% credible interval was calculated based on the equal-tail method. The analysis was performed based on 4 assumptions (mild to large) of the between trial standard deviation: 0.125 for mild, 0.25 for moderate, 0.5 for substantial, and 1 for large. CI, confidence interval; HORIZON, Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly; ITT, intentto-treat; mITT, modified ITT; PFT, Pivotal Fracture Trial; RFT, Recurrent Fracture Trial.
